Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium
Pulnovo Medical, a Chinese pulmonary hypertension (PH) has secured over USD 100 million in an...
Eli Lilly Launches Omvoh (Mirikizumab) in China for Inflammatory Bowel Disease – IL-23p19 Antagonist Targets Ulcerative Colitis and Crohn’s Disease Following February Approval
Eli Lilly & Co. (NYSE: LLY) has officially launched Omvoh (mirikizumab) in China for the...
SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners
SenseTime, a leading Chinese smart diagnosis and treatment solution provider, has completed its Series A...
Kanghong Pharmaceutical Receives FDA Clearance for KHN921 Gene Therapy Trial in MYBPC3-Associated Hypertrophic Cardiomyopathy – Precision AAV Vector Targets Myocardial Tissue
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced it has received Investigational New Drug...
Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) successfully completed its initial public offering...
China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores
The National Medical Products Administration (NMPA) this week released the draft proposal “Appendix to the...
Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining...
Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026
Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299/MK-2010, a PD-1/VEGF bispecific antibody...
Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio
Eli Lilly & Co. (NYSE: LLY) is reportedly engaged in advanced negotiations to acquire Kelonia...
AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products
AbbVie Inc. (NYSE: ABBV), the US pharmaceutical giant, has announced a strategic partnership with the...
Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform
Annoroad Gene Technology (Beijing) Co., Ltd., a leading Chinese provider of integrated life science sequencing...
Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a...
Sunshine Lake Pharma Secures NMPA Approval for In-House Developed Premixed Insulin 30R Prefilled Pen
Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its in-house developed isophane protamine recombinant...
Hansoh Pharma’s B7-H3 ADC HS-20093 Secures Fourth NMPA Breakthrough Therapy Designation for NSCLC Combination Therapy
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) has announced that its investigational antibody-drug conjugate (ADC),...
Hengrui Pharma’s Nectin-4 ADC SHR-A2102 Granted Second NMPA Breakthrough Therapy Designation for Cervical Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 therapeutic...
Abbott Reports 3.8% YOY Revenue Growth in Q1 2026, Led by Diagnostics and Medical Devices
Abbott Laboratories (NYSE: ABT) announced its financial results for the first quarter of 2026, reporting...
Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials
Tigermed Consulting Co., Ltd. (SHE: 300347), a leading Chinese Contract Research Organization (CRO), has announced...
Amoytop Biotech Inks $445M Deal with Aligos for China Rights to Novel Hepatitis B Capsid Modulator Pevifoscorvir
Amoytop Biotech Co., Ltd. (SHA: 688278), a leading Chinese biopharmaceutical company, has entered into a...
Changchun High & New Tech Gains NMPA Clearance for GenSci136 Phase I/II Trial in Generalized Myasthenia Gravis
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a major Chinese biopharmaceutical company,...
Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy’s Molteni Farmaceutici
Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new...